Pisit Pitukcheewanont
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Pisit Pitukcheewanont | |
|---|---|
| Born | |
| Nationality | Thai |
| Other names | Dr. Duke |
| Citizenship | United States, Thailand |
| Education | Chiang Mai University (MD) Mahidol University (Pediatrics Medicine) The University of Tennessee (Fellowship in Pediatric Endocrinology and Metabolism) |
| Organization | Human Growth Foundation (Current President) |
| Known for | Bone and Endocrinology Research |
| Medical career | |
| Profession | Physician, Professor of Pediatric Medicine & President (HGF) |
| Institutions | Keck School of Medicine USC, Children's Hospital Los Angeles, |
| Sub-specialties | Bone Health, Bone Metabolism, and Endocrinology |
Pisit Pitukcheewanont, also known as "Dr. Duke"[1] is a Doctor of Medicine, a former professor of Clinical Pediatrics and a philanthropist.[2] Currently, he is an adjunct professor of Clinical Pediatrics[3] at Keck School of Medicine of the University of Southern California, the president of a nonprofit organization, The Human Growth Foundation[2] and Senior Vice President of Global Clinical Development and Medical Affairs Lumos Pharmacy.[4]
Biography
[edit]Pisit Pitukcheewanont ("Dr. Duke") was born in Surin, Thailand. He received his early education from Triam Udom Suksa, Bangkok, Thailand. He attended Chiang Mai University, Chiang Mai, and completed his doctorate thesis M.D., followed by a residency in Pediatrics at the department of pediatrics Faculty of Medicine Chiang Mai University, a Fellowship of Pediatric Endocrinology, and Metabolism at Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand. He moved to the United States in 1994 and completed a second Fellowship of Clinical and Research at the Division of Endocrinology, Metabolism, and Nutrition, Department of Pediatrics, University of Tennessee Medical Center, Knoxville, TN. He then completed a second residency in Pediatrics (PL-3)[5] at University of Tennessee, LeBonheur Children’s Medical Center, Memphis, TN. After settling in Los Angeles CA, he went rapidly through the academic hierarchy steps from assistant professor to full professor of Clinical Pediatrics at University of Southern California, Keck School of Medicine, in addition to his professorship at USC, earlier he was senior investigator, Clinical Director of Pediatric Bone Program and Co-Director of Pediatric Endocrine Fellowship and Training Program Program at Keck School of Medicine. He was also a practicing pediatric endocrinologist at the Children's Hospital Los Angeles 1998-2018 and was the Executive Board of Director for Thai-Americans Physicians Foundation, 2008-2011.[6]
Research
[edit]His clinical and research interests have been in pediatric endocrinology especially as it relates to growth and bone health and bone development, the pathogenesis, prevention, and treatment of childhood osteoporosis; and metabolic bone disorders in pediatric patients. He has participated in many major clinical trials related to growth and bone disorders for many years. He has over 70 publications in peer-reviewed, non-peer-reviewed, book chapter. His recent publications have been concerned with the disparities resulting from the various methods of measuring bone density and pediatric bone disorders.
Honors
[edit]1980 "American Field Service (AFS): Scholarship to the United States",1984 "Scholarship to Fukui Medical School, University of Fukui, Fukui, Japan",1985-1987 "The Leader of Institute of Foreign Medical Affairs at Faculty of Medicine, Chiang Mai University",1992-1993 "Fellowship Grant in Pediatric Endocrinology and Metabolism, University of Tennessee Medical Center, Knoxville, TN, 1995 "The Lawson Wilkins Pediatric Endocrine Society Travel Grant Award, 2000-2002 "Mentor Junior Faculty Academic Career Development Award, Keck School of Medicine, 2003-Present "Best Doctors In America, 2007-Present", 2007–Present "America’s Top Pediatricians", 2008 "Thai American Physicians Foundation (TAPF) Medical Research Award", 2008 "Thai-American Visiting Professor Award", 2008–Present "Southern California Super Doctors" 2008–Present "President of Human Growth Foundation" 2011 - present "Madison’s Who’s Who in Medicine", 2017–present "Member of Society of Pediatric Research (SPR) Skirball Mentorship Award"
Publications
[edit]He has a substantial record of scholarly publications, with over 70 scientific papers to his credit. He has also served as the editor of multiple books, including electronic volumes, and his research has been widely cited in the scientific community. He is considered to be one of the most well-known physician-scientists in the fields of Clinical Pediatrics, Bone, Endocrinology, and Metabolism Medicine. His work has been featured in prestigious journals such as the Journal of Pediatric Endocrinology and the American Journal of Medical Genetics, among others.
| Year | Articles | Credit | Ref |
|---|---|---|---|
| 2022 | Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study | Co-author | [7] |
| 2021 | Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension | Co-author | [8] |
| 2021 | Economic Burden of Growth Hormone Deficiency in a US Pediatric Population | Co-author | [9] |
| 2021 | Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia | Co-author | [10] |
| 2021 | Economic burden of growth hormone deficiency in a US pediatric population | Co-author | [11] |
| 2020 | Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial | Co-author | [12] |
| 2020 | OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial | Co-author | [13] |
| 2020 | SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta | Co-author | [14] |
| 2019 | Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial | Co-author | [15] |
| 2019 | Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period | Co-author | [16] |
References
[edit]- ^ "Pisit Pitukcheewanont, MD". Children’s Hospital Los Angeles. 2022-01-11. Retrieved 2023-01-21.
- ^ a b "Our Team". HGF. Retrieved 2023-01-21.
- ^ "Pediatrics – Childrens Hospital of Los Angeles – Departments Directory". departmentsdirectory.usc.edu.
- ^ "Our Team | Lumos Pharma". lumos-pharma.com. 2019-12-17. Retrieved 2023-01-21.
- ^ "2008 Awards | Thai-American Physicians Foundation". Retrieved 2023-01-26.
- ^ "TAPF Medical Research Award". Children’s Hospital Los Angeles. 2015-11-11. Retrieved 2022-12-27.
- ^ "Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension". ResearchGate.
- ^ "Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension". ResearchGate.
- ^ "Economic Burden of Growth Hormone Deficiency in a US Pediatric Population". ResearchGate.
- ^ "Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia". ResearchGate.
- ^ "Economic burden of growth hormone deficiency in a US pediatric population". ResearchGate.
- ^ "Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial". ResearchGate.
- ^ "OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial". ResearchGate.
- ^ "SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta". ResearchGate.
- ^ "Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial". ResearchGate.
- ^ "Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period". ResearchGate.